AU Patent

AU2010278897A1 — Therapeutic agents for reducing parathyroid hormone levels

Assigned to Kai Pharmaceuticals Inc · Expires 2012-02-23 · 14y expired

What this patent protects

Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X - X - X - X - X - X - X, wherein the X subunit comprises a thiol-containing moiety and the distribution of charg…

USPTO Abstract

Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X - X - X - X - X - X - X, wherein the X subunit comprises a thiol-containing moiety and the distribution of charge on the X-X subunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.

Drugs covered by this patent

Patent Metadata

Patent number
AU2010278897A1
Jurisdiction
AU
Classification
—
Expires
2012-02-23
Drug substance claim
No
Drug product claim
No
Assignee
Kai Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.